LivingGLP1
Study S002674

BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)

ClinicalTrials.gov record

Registration

Registration
NCT07226947
Acronym
BICEP
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Status
RECRUITING
Enrollment
100
Start
2025-11-24
Primary completion
2027-06
Lead sponsor
Massachusetts General Hospital
Conditions
Obesity; Body Composition
Interventions
DEVICE:Smartwatch activity and body composition monitor; BEHAVIORAL:General guidance on recommended exercise
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Lean mass (kg) [6 months]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0003953Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, Diabetes care
2024Randomized trialPMID 38687506DOIregistry reference BACKGROUND:38687506
R0008662Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Lancet (London, England)
2023Randomized trialPMID 37385275DOIregistry reference BACKGROUND:37385275
R0015688Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, The New England journal of medicine
2023Randomized trialPMID 37366315DOIregistry reference BACKGROUND:37366315
R0010987Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, The New England journal of medicine
2022Randomized trialPMID 35658024DOIregistry reference BACKGROUND:35658024
R0023399Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, The New England journal of medicine
2021Randomized trialPMID 33567185DOIregistry reference BACKGROUND:33567185